

HOW DO WE DEVELOP SAFE, EFFECTIVE

COVID-19 VACCINES

IN RECORD-BREAKING TIME?

+240
vaccine candidates

HEAD START

- Use previous MERS/SARS vaccine research.
- Go straight to clinical trials

Research/Pre-trials

Phase 1 trials

49
candidates

Phase 2 trials

37
candidates

Phase 3 trials

27
candidates

OVERLAPPING PHASES

- of clinical trials save time, large trial size allows for more data to be collected in less time

EMERGENCY USE AUTHORIZATION

- Rapid authorization process allows a vaccine to be distributed while post clinical trial research continues

EUA

3

Post-trial follow up

Build factories

Manufacture vaccines

Phased Distribution

**BUILD FACTORIES
EARLY**

PRODUCE VACCINES QUICKLY

(only those vaccines proven safe and effective in clinical trials will be distributed)

SET UP DISTRIBUTION INFRASTRUCTURE EARLY

allows for rapid deployment of vaccines once approved

PHASED VACCINE DELIVERY

Distribute vaccines to priority groups like front-line workers; expand in phases until everyone has access